Smith Justin Adam 4

What Happened

• Justin Adam Smith, a director of Journey Medical Corp (DERM), was granted 10,000 restricted stock units (RSUs) on June 25, 2026. The grant is reported as an award (transaction code A) at $0.00 per share, so there was no cash purchase or sale and no immediate taxable sale value recorded on the Form 4.

Key Details

• Transaction date: June 25, 2026; Form 4 filed June 26, 2026 (timely filing).
• Transaction type/code: Award/Grant (A).
• Amount: 10,000 restricted stock units; reported acquisition price $0.00 (typical for RSU grants).
• Vesting: Per footnote, the 10,000 RSUs vest in full on June 25, 2027.
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Other notes: Footnote indicates inclusion of restricted stock units that vest over various periods (F2) — this grant specifically vests in one year (F1).

Context

• RSUs are a form of equity compensation that convert to shares upon vesting; they do not represent immediately tradable shares and typically have no cash outlay by the insider at grant. Such awards are common for compensation and retention and are informational rather than a direct buy/sell signal.